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Abstract
Background: In women with multiple sclerosis (MS), depres-
sion and sexual dysfunction (SD) are common. Whether SD 
promotes depression or vice versa remains unclear despite 
therapeutic relevance. Therefore, we aimed to assess wheth-
er SD more likely triggers depression or vice versa. Methods: 
In 83 female MS patients and 21 age-matched healthy wom-
en, we assessed depression, using the Beck Depression In-
ventory-V (BDI-V), and SD using the Female Sexual Function 
Index (FSFI). We diagnosed depression with BDI-V-scores >35 
and SD with FSFI scores < 26.55. We divided patients into 
groups with and without SD, with and without depression. 
Between groups, we compared prevalence of SD and depres-
sion (Fisher’s-exact-test), age, MS-duration, MS-severity, BDI-
V-, and FSFI scores (Mann-Whitney U-test; significance: p < 
0.05). Results: A total of 37/83 MS patients and 1/21 controls 
had SD; 28/83 patients and 3/21 controls had depression; 
51.4% patients with SD but only 19.6% without SD had de-
pression (p = 0.003). SD was present in 67.9% depressed and 
32.7% non-depressed patients. BDI-V-scores were higher in 
patients with SD than in patients without SD. FSFI scores 
were lower in depressed than non-depressed patients. Con-
clusion: In conclusion, SD was more common than depres-
sion. SD afflicted 67.9% depressed MS patients and was also 
more common in non-depressed MS patients than controls. 
SD may occur independently from depression while in-
creased depressiveness seems linked to coexistent SD.
© 2018 S. Karger AG, Basel
Introduction
In multiple sclerosis (MS), depression and sexual dys-
function (SD) are common [1, 2]. Depending on param-
eters such as patient age, disease severity, hospital or out-
patient based settings, between 15.7 and 50% of the fe-
male MS patients suffer from depression [1, 3–7]. 
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Depression may be due to psychological, psychosocial 
as  well as organic pathologies arising from MS-specif-
ic  brain lesions [1]. Depression affects cerebral neuro-
physiology [8], bodily functions [9] and psychosocial re-
lationships [10], and may thus further SD in female MS 
patients.
Various studies show that the prevalence of SD among 
female MS patients ranges between 50 and 85% [2, 11–
13]. Again, SD may be multifactorial. In addition to MS-
related cerebral or spinal lesions [11, 14–17], psychologi-
cal or social problems [18], physical complications of MS, 
such as bladder and bowel dysfunction [19, 20] or spastic-
ity, may give rise to SD [21, 22].
In the general population, SD and depression are con-
sidered to be associated with each other due to a known 
bidirectional interdependence between depression and 
SD [12, 23]. In female MS patients, previous studies also 
suggest an interdependence of SD, depression, disease se-
verity, and duration [12, 13, 24]. However, it is so far un-
clear whether depression in female MS patients might be 
secondary to centrally induced SD, or whether SD might 
result from MS-related depression. This differentiation is 
clinically relevant since treatment of SD secondary to de-
pression and treatment of depression secondary to SD 
may differ significantly [25], particularly since many an-
tidepressant drugs aggravate SD [25, 26].
Several studies show that SD in MS patients is often 
associated with MS lesions in cerebral or spinal cord areas 
contributing to central pathways of sexual function [11, 
14–17, 27]. Our group recently demonstrated associa-
tions between the site of MS-specific cerebral lesions and 
specific disorders of female sexual function, such as 
arousal, lubrication or orgasmic dysfunction [14, 15]. 
Based on our previous studies [14, 15, 28], we hypothesize 
that primary SD [18] due to central MS lesions is a major 
contributing factor of depression in female MS patients.
We, therefore, evaluated whether there is evidence 
supporting the hypothesis that SD in female MS patients 
may cause depression or whether SD and depression are 
simply associated with each other due to a bidirectional 
interdependence between depression and SD [23, 25, 27].
Patients and Methods
Patients with MS and Healthy Women
A total of 83 women, aged 19–65 years (median age 36.2 years; 
interquartile range [IQR] 29.3–42.5 years), who had been diag-
nosed with MS according to the revised McDonald criteria [29] and 
21 healthy, age-matched women (median age 33.2 years; IQR 28.2–
50.3 years) participated in the questionnaire-based study. All 
 patients were treated at the MS center of the Department of 
 Neurology at the University Erlangen-Nuremberg, Erlangen, 
 Germany. Of which, 76 patients had relapsing-remitting MS, 6 pa-
tients had secondary progressive MS, 1 patient had primary pro-
gressive MS. A total of 32 patients received interferon beta, 19 pa-
tients were treated with Natalizumab, 16 patients received no ther-
apy, and 16 patients received Fingolimod, Mitoxantrone, 
Glatiramer acetate, or other disease modifying therapies shown in 
Table 1.
Women younger than 19 years or older than 65 years and pa-
tients with other neurological disorders and diseases or on medica-
tion possibly interfering with autonomic cardiovascular modula-
tion, including antidepressants, were excluded from the study. None 
of the participants had received any antidepressant therapy or had 
been treated because of SD. The study was approved by the Ethics 
Committee of the University of Erlangen-Nuremberg, and all par-
ticipants had given written informed consent according to the Dec-
laration of Helsinki after a detailed explanation of the study purpose 
and contents. All participants underwent physical and neurological 
examinations. In the patients, MS severity was scored according to 
the Expanded Disability Status Scale (EDSS) ranging from 0 to 10. 
Scores from 0 to 4.5 indicate that patients still have the full capabil-
ity of walking; higher scores indicate more severe handicap [30].
Assessment of SD
To assess prevalence and severity of SD in healthy participants 
and MS patients, we applied the Female Sexual Function Index 
(FSFI), a widely used standardized 19-item self-report question-
naire validated for the general population [31]. The FSFI covers the 
6 sexual domains: desire, arousal, lubrication, orgasm, satisfaction, 
and pain [31]. Desire is evaluated by 2 questions, arousal by 4 ques-
tions, lubrication by 4 questions, orgasm by 3 questions, satisfac-
tion by 3 questions, and pain by 3 questions. Each question can be 
answered with scores from 0 or 1 to 5, with higher values indicating 
better function and less pain during sexual activity or intercourse. 
The total score of each of the 6 domains is adjusted by a validated 
correction factor that assigns a maximum score of 6 to each of the 
6 domains. Thus, the total maximum FSFI score is 36. The lower 
the scores, the more severe is the female SD or the dysfunction in 
one of the 6 domains [31]. Female SD is diagnosed when the total 
FSFI score is below 26.55 points [32].
Table 1. Disease modifying therapy in our 83 female patients with 
multiple sclerosis
Medication Number of patients, n (%)
Interferon beta 32/83 (38.6)
Natalizumab 19/83 (22.9)
No medication 16/83 (19.3)
Fingolimod 4/83 (4.8)
Mitoxantrone 3/83 (3.6)
Glatiramer acetate 2/83 (2.4)
Daclizumab 2/83 (2.4)
Teriflunomid 2/83 (2.4)
Azathioprine 1/83 (1.2)
Dimethyl fumarate 1/83 (1.2)
Rituximab 1/83 (1.2)
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To evaluate depressiveness, all participants were asked to fill 
out an abridged 20-item version of the Beck Depression Inven-
tory (BDI-V) [33]. The 20 questions evaluate the presence and 
severity of depressive symptoms based on depression criteria of 
the Diagnostic and Statistical Manual of Disorders (DSM-IV). 
Each question can be scored from 0 to 5, with higher values in-
dicating more severe symptoms and a sum scores above 35 in-
dicating clinically relevant depression with a 90% probability 
[34].
Based on FSFI scores below or at and above 26.55, we divided 
patients into groups with SD and without SD. Based on BDI-V 
scores above or at and below 35, we assigned patients to the 
groups with or without depression. Finally, we also assigned pa-
tients to a group meeting criteria of both SD and depression. Be-
tween the groups, we compared the prevalence of SD and depres-
sion, as well as severity of depressiveness, as assessed by BDI-V 
scores, and of SD, as assessed by FSFI scores; in addition, we 
compared age, disease duration and EDSS scores between the 
groups.
In all 83 patients and in the above subgroups, we calculated cor-
relations between FSFI scores, BDI-V scores, patient age, disease 
duration and severity to further explore whether there are associa-
tions supporting the hypothesis that SD might trigger depression 
or vice versa.
Statistical Analysis
To test data for normal distribution, we used the Shapiro-Wilk 
test. Not normally distributed data are presented as median and 
IQR; normally distributed data are presented as mean and stan-
dard deviation. To compare the prevalence of categorical data, 
such as prevalence of depression or SD, we used the Fisher’s exact 
test. To compare scores and data between healthy participants and 
the patient groups without and with depression, and data between 
healthy participants and patient groups without and with SD, we 
used the Kruskal-Wallis test for not normally distributed data and 
analysis of variance for normally distributed data. To compare 
data between 2 of the 3 groups, we used the Mann-Whitney U-test 
for not normally distributed data and t tests for normally distrib-
uted data.
To calculate correlations, we used the Spearman rank correla-
tion test for not normally distributed data. Statistics were calcu-
lated with a commercially available statistical program (IBM SPSS 
Statistics for Windows, Version 20.0. Armonk, NY, USA). Signifi-
cance was assumed for p < 0.05.
Results
All participants filled out questionnaires. The age did 
not differ between healthy participants (median age 36.2 
years, IQR 29.3–42.5 years) and patients (median age 33.2 
years, IQR 28.2–50.3 years; Mann-Whitney U-test: p > 
0.05).
Prevalence of SD and Depression in 83 MS Patients 
and 21 Controls (Table 2)
SD was prevalent in 37 of the 83 MS patients (44.6%) 
and 1 of the 21 healthy women (4.8%; Fisher’s exact test: 
p < 0.001). Depression was prevalent in 28 of the 83 pa-
tients (33.7%) and in 3 of the 21 healthy participants (14.3 
%), one of whom also had SD (Fisher’s exact test: p = 
0.066).
A total of 19 of the 37 (51.4%) patients with SD (i.e., 
22.9% of all 83 patients) also had depression while only 
nine of the 46 (19.6%) patients without SD had depres-
sion (Fisher’s exact test: p = 0.003). Prevalence of depres-
sion was also higher in the 37 patients with SD than in 
healthy women but did not differ between the 46 MS pa-
tients without SD and healthy women.
A total of 19 of the 28 patients with depression also had 
SD (67.8%). And 18 of the 55 patients (32.7%) without 
depression had SD (2-sided Fisher’s exact test: p = 0.005). 
Table 2. Prevalence of SD and depression in 83 female MS patients and 21 healthy women
Parameters MS patients with
SD (n = 37) [1]
MS patients without
SD (n = 46) [2]
Healthy women
(n = 21) [3]
Comparison between groups
Fisher’s exact test p value 
[1] vs. [2] [1] vs. [3] [2] vs. [3]
Depression, n (%) 19/37 (51.4) 9/46 (19.6) 3/21 (14.3) 0.003 0.011 0.738
No depression, n (%) 18/37 (48.6) 37/46 (80.4) 18/21 (85.7) 0.003 0.011 0.738
Parameters Depressed
MS patients
(n = 28) [1]
Non-depressed 
MS patients
(n = 55) [2]
Healthy
women
(n = 21) [3]
Comparison between groups
Fisher’s exact test p value
[1] vs. [2] [1] vs. [3] [2] vs. [3]
SD, n (%) 19/28 (67.9) 18/55 (32.7) 1/21 (4.8) 0.003 <0.001 0.016
No SD, n (%) 9/28 (32.1) 37/55 (67.3) 20/21 (95.2) 0.003 <0.001 0.016
MS, multiple sclerosis; SD, sexual dysfunction.
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SD was more prevalent among the 28 MS patients with 
depression as well as the 55 patients without depression 
than among healthy women (Fig. 1).
Severity of SD and Depressiveness in 37 Patients  
with SD, 46 Patients without SD, and in  
21 Controls (Table 3a)
Age did not differ between the 37 patients with SD, 
the 46 patients without SD, and the 21 healthy partici-
pants, and disease duration and disability (as measured 
by EDSS) did not differ between the patients with and 
without SD. However, SD was more severe, that is, FSFI 
scores were significantly lower in the 37 patients with SD 
than the 46 patients without SD or the 21 healthy par-
ticipants while FSFI scores did not differ between pa-
tients without SD and healthy participants. BDI-V scores 
were also higher in the 37 patients with SD (median 36; 
IQR 25.5–49.5) than in the 46 patients without SD (me-
dian 20; IQR 12–29) and the 21 healthy participants (me-
dian 18; IQR 10.5–28.5). However, BDI-V scores did not 
differ between patients without SD and the healthy par-
ticipants. 
Severity of Depressiveness and SD in 28 Depressed,  
55 Non-Depressed Patients, and in  
21 Controls (Table 3b)
Again, age did not differ between the 28 depressed, 55 
non-depressed patients, and 21 controls, and disease du-
ration and disability as measured by EDSS did not differ 
between depressed and non-depressed patients.
As expected, BDI-V scores were higher in the 28 de-
pressed patients than in the 55 non-depressed patients 
and the 21 controls while BDI-V scores did not differ be-
tween non-depressed patients and controls. In the 28 de-
pressed patients, FSFI scores were also significantly lower 
(median: 21.0: IQR 5.9–27.8) than in the 55 non-de-
pressed MS patients (median: 29.6; IQR: 24.4–32.6; p = 
0.001) or the controls (median 31; IQR 29.3–33.5). Again, 
FSFI values did not differ significantly between non-de-
pressed patients and controls. 
Correlations between Age, Disease Duration, Disease 
Severity, Depressiveness, and SD (Table 4)
FSFI scores inversely correlated with age in the group 
comprising all patients and in the subgroups with SD 
and/or depression. In contrast, FSFI scores only corre-
lated inversely with disease severity in the group compris-
ing all patients and the subgroup with depression. Simi-
larly, FSFI scores correlated inversely with BDI-V scores 
only in the group comprising all patients. Otherwise, 
BDI-V scores correlated only with disease severity in the 
group comprising all patients.
Discussion
In our patients, SD and depression were not only more 
prevalent than in the controls but patients were more fre-
quently afflicted by SD (44.6%) than depression (33.7%). 
Our data again confirm the previously described associa-
tion between SD and depression in female MS patients 
[12, 23] and show a similar prevalence of SD and depres-
sion in our patients as in previous studies which suggest 
that SD prevalence may vary considerably and affect 40–
80% of female MS patients [2, 12, 21, 24, 35]. Similarly, 
prevalence of depression varied in previous studies with 
patient age, MS severity, hospital or out-patient based 
study-setting, and ranged from 15.7 to 50% [1, 3–7].
In our patients, MS severity also affected the severity 
of SD and depression, as shown by the correlation be-
tween EDSS scores and FSFI  as well as BDI-V scores (Ta-
ble 4) [20, 24].  
However, in contrast to previous studies, we not only 
saw an increased prevalence and close interdepen-
dence of depression and SD in the female MS patients 
[1, 3, 4], but also the differentiation of patients into sub-
groups with and without SD as well as subgroups with 
and without depression. This strongly suggests that SD 
is more closely linked to depression than vice versa (Ta-
ble 2). 
With SD only
With both SD and depression
With depression only
With neither SD nor depression
Fig. 1. Prevalence of sexual dysfunction and depression in 83 fe-
male patients with multiple sclerosis (MS). Among 83 female MS 
patients, 18 patients had sexual dysfunction but no depression 
(gray shade), 19 patients had both sexual dysfunction and depres-
sion (black shade), 9 patients had depression but no sexual dys-
function (light gray), and 37 patients neither had sexual dysfunc-
tion nor depression.
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Table 3.   
a. Age, disease duration, EDSS, BDI-V-scores, and FSFI scores in 37 MS patients with sexual dysfunction defined by FSFI scores below 
26.55, in 46 MS patients without SD defined by FSFI scores at or above 26.55, and in 21 healthy women
Parameters MS patients
with SD
(n = 37) [1]
MS patients
without SD
(n = 46) [2]
Healthy
women
(n = 21) [3]
Comparison between groups*, † 
p value
[1] vs. [2] [1] vs. [3] [2] vs. [3]
Age, years 39.9 (31.5–43.9) 34.6 (27.3–42.0) 33.2 (28.2–50.3) 0.162
MS, months 58.5 (10.7–112.5) 43.0 (9.0–94.5) NA 0.651 NA NA
EDSS 3 (1.5–6) 2 (1–4) NA 0.111 NA NA
BDI-V 36 (25.5–49.5) 20 (12–29) 18 (10.5–28.5) <0.001 <0.001 0.620
FSFI 16.4 (4.7–23.4) 31.4 (29.2–33.2) 31 (29.3–33.5) 0.001 <0.001 0.962
b. Age, disease duration, EDSS, BDI-V-scores, and FSFI scores in 28 depressed MS patients defined by BDI-V scores above 35, in 55 
non-depressed MS patients, and in 21 healthy women
Parameters Depressed
MS patients
(n = 28) [1]
Non-depressed
MS patients
(n = 55) [2]
Healthy
women
(n = 21) [3]
Comparison between groups*, †
p value
[1] vs. [2] [1] vs. [3] [2] vs. [3]
Age, years 33.3 (28.7–41.2) 38.5 (29.3–43.0) 33.2 (28.2–50.3) 0.471
MS duration, months 43 (10–93) 52.5 (9.8–129.8) NA 0.829 NA NA
EDSS 3 (1.5–6) 2 (1–4) NA 0.154 NA NA
BDI-V 49.5 (42.3–58.5) 20 (12–27) 18 (10.5–28.5) <0.001 <0.001 0.862
FSFI 21.0 (5.9–27.8) 29.6 (24.4–32.6) 31 (29.3–33.5) 0.001 <0.001 0.073
Data are expressed as median values and interquartile ranges. Significant  differences were indicated in bold.* Kruskal-Wallis H test was used for the comparison between the 3 groups.† Mann-Whitney U test was used for the post-hoc comparison between 2 groups.
BDI, Beck depression inventory; EDSS, expanded disability status scale; FSFI, female sexual function index; NA, not available.
Table 4. Correlation of FSFI scores with age, disease duration, EDSS, and BDI-V scores and correlation of BDI-V scores with age, 
disease duration, and EDSS scores in 
A. 83 female MS patients 
B. 37 female MS patients with sexual dysfunction defined by FSFI scores below 26.55, and 
C. 28 female MS patients with depression defined by BDI-V scores above 35 
D. 19 female MS patients with both sexual dysfunction and depression
Age Disease duration EDSS BDI-V
rho p value rho p value rho p value rho p value
FSFI
A. (n = 83) –0.271 0.007 –0.026 0.825 –0.243 0.031 –0.489 0.000
B. (n = 37) –0.471 0.003 0.094 0.596 –0.378 0.025 –0.172 0.310
C. (n = 28) –0.478 0.010 –0.047 0.816 –0.062 0.757 0.054 0.786
D. (n = 19) –0.673 0.002 –0.113 0.646 –0.181 0.459 0.043 0.862
BDI-V
A. (n = 83) –0.070 0.527 0.056 0.635 0.233 0.039 N/A N/A
B. (n = 37) –0.172 0.308 –0.078 0.660 0.141 0.419 N/A N/A
C. (n = 28) –0.084 0.671 –0.203 0.310 0.082 0.685 N/A N/A
D. (n = 19) 0.218 0.370 –0.043 0.861 0.119 0.628 N/A N/A
FSFI, female sexual function index; BDI, Beck depression inventory; EDSS, expanded disability status scale; rho, Spearman rank cor-
relation rho; N/A, not available. Significant  differences were indicated in bold.
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A total of 51.4% of our patients with SD also suffered 
from depression (Table 2), and depressiveness was more 
severe in patients with SD than in those without SD (Ta-
ble 3a). In fact, in patients with normal sexual function 
depressiveness did not differ from depressiveness in con-
trols (Tables 2, 3b). In contrast, SD was not only more 
prevalent in the patient subgroup without depression 
than in the control group (32.7 vs. 4.8%; Table 2) but also 
more severe (2-sided Fisher’s exact test: p = 0.016; Table 
3b). In the subgroup of depressed patients, SD was even 
more prevalent (67.9%) and again more severe than in the 
subgroup without depression (Tables 2, 3b). 
While FSFI scores reflecting sexual function corre-
lated negatively with patient age, BDI-V scores reflect-
ing depressiveness neither correlated with patient age 
nor disease duration but only with disease severity. The 
age-related decline in sexual function can be explained 
by the age-related decrease in sexual function in the 
general population [25, 27, 36]. However, the link be-
tween deteriorating sexual function, that is, decreasing 
FSFI scores and increasing depressiveness, that is, in-
creasing BDI-V scores was only significant for the en-
tire group of our 83 patients but not for the subgroups 
of depressed and non-depressed patients, nor for pa-
tients with and without SD (Table 4). This might be due 
to an inadequate sample size of the subgroups. There 
was no correlation between FSFI scores and BDI-V-
scores within the subgroup of the 28 depressed patients 
or within the subgroup of the 37 patients with SD. This 
might also suggest that the severity of 1 disorder does 
not necessarily influence the severity of the other disor-
der despite the above mentioned bidirectional interde-
pendence between depression and SD [12, 23]. Theo-
retically, SD and depression might trigger each other 
without mutually influencing the severity of the other 
disorder.
In summary, our data not only show that SD is more 
common than depression among female MS patients but 
show that depression without SD (9/46 patients) is nei-
ther more common nor more pronounced among our 
MS patients than among our healthy controls (3/21 wom-
en). In contrast, SD is not only closely linked to depres-
siveness and afflicts 67.8% of our depressed patients, but 
also occurred significantly more often in MS patients who 
have no depression than in our healthy controls (Tables 
2, 3). While SD occurs together with depression in most 
of our patients, SD may also occur without concomitant 
depression (Table 2). In contrast, prevalence and severity 
of depressiveness (Tables 2, 3a, 3b) seem to be associated 
with coexistent SD.
As mentioned earlier, the pathophysiology of SD and 
depression in MS may be multifactorial [1, 23] and, simi-
lar to the general population, may be based on a bidirec-
tional association between depression and SD [23]: indi-
viduals with depression have an increased risk of develop-
ing SD, while patients with SD are at an increased risk of 
depression [23]. In MS patients, not only psychological, 
somatic or social implications of MS contribute to de-
pression [1] and SD [23], but also MS-specific lesions, for 
example, in projection areas of the basal limbic system 
[37] give rise to depressive symptoms such as anhedo-
nia or depressed affect [1, 37–39]. In 109 women with MS, 
Gold et al. [38] found associations between depres-
sion and reduced thickness of the right hippocampus. In 
92 MS patients, Feinstein et al. [39] observed that in-
creased lesion volume in the right medial inferior frontal 
region was associated with depression [1, 39]. Berg et al. 
[37] reported associations between depression and in-
creased MS lesion load in the right temporal lobe in 78 
MS patients.
Similarly, central MS lesions are associated with SD 
[11, 16, 17]. Barak et al. [11] described associations of an-
orgasmia with brainstem lesions, lesions of the cortico-
spinal tract and also with the total lesion load. In female 
and male MS patients, Zivadinov et al. [16] and Zorzon et 
al. [17] found associations between SD and pontine le-
sions. Our group recently showed associations between 
the site of MS-specific cerebral lesions and female SD [14, 
15]. We found associations between right occipital le-
sions and impaired arousal and between left insular le-
sions and decreased lubrication [14]. In another study, we 
found that MS lesions in left temporal periventricular and 
right visual association areas compromise orgasmic func-
tion [15].
Based on our data, we assume that MS-specific lesions 
may contribute to SD which might entail depression, ei-
ther due to lesion sites that yield both SD and depression, 
or due to secondary and psychological sequelae of SD [25, 
27].
Our sample size was rather small due to our stringent 
criteria excluding participants with other diseases or on 
any therapy possibly influencing mood or sexual func-
tion. Still, our data suggest that SD is more common than 
depression among female MS patients. Moreover, the 
findings suggest that SD probably even triggers depres-
sion while the effect of depression on SD seems less prom-
inent. 
While we did not analyze the associations between 
specific central lesion sites in magnetic resonance images 
and depression or SD in this study, our previous studies 
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indicate a prominent influence of central MS lesions on 
sexual function [14, 15, 28]. Although EDSS scores were 
below 4 in most of our patients, 44.6% of patients fulfilled 
the SD criteria and 33.7% met the criteria for depression. 
As expected, there was a close link between SD and de-
pressiveness in the entire group of the 83 patients con-
firming the mutual interdependence of both disorders 
[12, 23].
However, only, those patients who had SD also had an 
increased prevalence and severity of depression (Table 2). 
In contrast, SD was more prevalent in the subgroups, re-
gardless of coexistent depression, than in controls (Table 
2). Thus, in our MS patients SD is not only more common 
than depression but our data suggest that SD may be a 
causative component of depression.
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